Propanc Biopharma, Inc. announced that it has entered into and closed a securities purchase agreement with returning investor 1800 Diagonal Lending, LLC to issue 15% Convertible promissory note at an issue price of $41,000 for the gross proceeds of $41,000 on May 31, 2024. The principal amount is $49,200. The Investor is entitled, at its option, at any time after cash payment, to convert any or all or any amount of the principal face amount of the Note then outstanding into shares of the company?s common stock at a price for each share of common stock at a price of of 65% multiplied by the lowest Trading Price for the common stock during the ten Trading Days prior to the Conversion Date (representing a discount rate of 35%).

The maturity date of the Note is April 15, 2025 and the note bears interest at a rate of 15% per annum. The note was issued pursuant to the private placement exemption from registration provided by Section 4(a)(2) of the Securities Act and/or by Rule 506 of Regulation D promulgated thereunder.